Compare Eli Lilly And Co (LLY) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ProShares UltraPro Short QQQ ETF — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while ProShares UltraPro Short QQQ ETF trades at $32.92 (market cap $2.23B). The key difference: Eli Lilly And Co is far larger — about 466.4× ProShares UltraPro Short QQQ ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| LLY | SQQQ | |
|---|---|---|
Market Cap | $1.04T | $2.23B |
Volume | 3,064,878 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $89.43 |
52-Week Low | $799.57 | $31.83 |
Typical Hold Time | 93 Days | 12 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
SQQQ trades at $32.95, up 2.71% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows no traditional financial ratios as it's an inverse leveraged product designed to move opposite the Nasdaq 100. Recent news highlights its role as a hedging tool against tech sector declines, with articles discussing strategic pairing with QQQ positions.
As a 3x leveraged inverse ETF, SQQQ carries significant risk from daily rebalancing and decay. It serves as a tactical tool for bearish Nasdaq 100 views or portfolio hedging, but requires active management. The primary risk remains volatility decay and timing sensitivity in a market where tech stocks have shown long-term growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
